4th Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Firm
Client
Income
—
Expenses
$1,300,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Education related to hepatitis C and HIV.

LobbyistCovered position, as disclosed
CHARLES M. CLAPTON —
COOKAB HASHEMI —
DAVID PULLIAM —

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; White House Office

Trade (domestic/foreign) TRD

International trade and protection of intellectual property; compulsory licensing and other IP issues in multiple countries.

LobbyistCovered position, as disclosed
CHARLES M. CLAPTON —
DAVID PULLIAM —

Contacted: Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); State, Dept of (DOS)

Copyright/Patent/Trademark CPT

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

LobbyistCovered position, as disclosed
CHARLES M. CLAPTON —
DAVID PULLIAM —

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; White House Office; U.S. Trade Representative (USTR); State, Dept of (DOS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE

Health Issues HCR

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CHARLES M. CLAPTON —
COOKAB HASHEMI —
DAVID PULLIAM —

Contacted: U.S. Trade Representative (USTR); Office of Management & Budget (OMB); White House Office; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Commerce, Dept of (DOC)

Bills named: S. 3013 (116th), H.R. 1643 (116th), S. 2543 (116th), H.R. 3 (116th), S. 1926 (116th)

Medicare/Medicaid MMM

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CHARLES M. CLAPTON —
COOKAB HASHEMI —
DAVID PULLIAM —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); White House Office

Bills named: H.R. 3 (116th), H.R. 19 (116th), S. 3129 (116th), H.R. 259 (116th), S. 2543 (116th)

Budget/Appropriations BUD

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act

LobbyistCovered position, as disclosed
CHARLES M. CLAPTON —
COOKAB HASHEMI —
DAVID PULLIAM —

Contacted: Office of Management & Budget (OMB); Commerce, Dept of (DOC); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); U.S. Trade Representative (USTR); White House Office

Bills named: H.R. 4378 (116th), H.R. 1865 (116th), H.R. 3055 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.